# US 2022/0033490 A1 · Methods and compositions for treating cancer using chrna6 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033490 A1
- Document ID: US20220033490A1
- Status: Published application
- Kind: A1
- Application number: 16/966,072
- Filed: 2019-01-31
- Published: 2022-02-03
- Earliest claimed: 2018-01-31
- Assignees: Flagship Pioneering Innovations V, Inc.
- Applicants: Flagship Pioneering Innovations V, Inc.
- Inventors: Avak KAHVEJIAN; Jordi MATA-FINK; Jonathan Barry HUROV; Chengyi Jenny SHU; Manuel Andreas FANKHAUSER; Julian Alexander STANLEY
- Web page: https://patentgrep.com/patent/US20220033490A1

## CPC

- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/008: {comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]}
- A61K 9/0085: {Brain, e.g. brain implants; Spinal cord}
- A61K 31/4425: Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
- A61K 38/1767: {from invertebrates}
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods for treating cancer using a6*nAChR inhibitors, such as a6*nAChR inhibitory antibodies, among others. The invention also features compositions containing a6*nAChR inhibitors, methods of diagnosing patients with a6*nAChR-associated cancer, and methods of predicting the response of cancer in a subject to treatment with a6*nAChR inhibitors.

## Claims

### Claim at position 1

1-123. (canceled)

### Claim 124

A method comprising administering to a subject an α6-containing nicotinic acetylcholine receptor (α6*nAChR) inhibitor, wherein the subject has a tumor comprising tumor infiltrating regulatory T cells (Tregs) that express α6*nAChR.

### Claim 125 (depends on 124)

The method of claim 124, wherein the α6*nAChR inhibitor is administered in an amount effective to reduce Treg-mediated immunosuppression of CD8+ T cell activity.

### Claim 126 (depends on 124)

The method of claim 124, wherein the α6*nAChR inhibitor is administered in an amount effective to increase CD8+ T cell activation by at least 1.1 fold, relative to a control.

### Claim 127 (depends on 124)

The method of claim 124, wherein the α6*nAChR inhibitor is administered in an amount effective to increase CD8+ T cell secretion of IFNγ by at least 1.1 fold, relative to a control.

### Claim 128 (depends on 124)

The method of claim 124, wherein the tumor is a cancer.

### Claim 129 (depends on 128)

The method of claim 128, wherein the cancer is a colorectal cancer.

### Claim 130 (depends on 128)

The method of claim 128, wherein the cancer is a non-small cell lung cancer.

### Claim 131 (depends on 124)

The method of claim 124, wherein the α6*nAChR inhibitor is a small molecule.

### Claim 132 (depends on 124)

The method of claim 124, wherein the α6*nAChR inhibitor is α-conotoxin PIA.

### Claim 133 (depends on 124)

The method of claim 124, wherein the α6*nAChR inhibitor is an antibody that specifically binds to α6*nAChR.

### Claim 134 (depends on 124)

The method of claim 124, wherein the α6*nAChR inhibitor is a programmable nuclease.

### Claim 135 (depends on 134)

The method of claim 134, wherein the programmable nuclease an RNA-guided nuclease.

### Claim 136 (depends on 135)

The method of claim 135, wherein the RNA-guided nuclease is Cas9.

### Claim 137 (depends on 124)

The method of claim 124, wherein the α6*nAChR inhibitor is administered locally.

### Claim 138

A method comprising administering to a subject an α6*nAChR inhibitor, wherein the subject has a cancer comprising tumor infiltrating Tregs that express α6*nAChR, and wherein the α6*nAChR inhibitor is administered in an amount effective to increase CD8+ T cell secretion of IFNγ by at least 1.1 fold, relative to a control.

### Claim 139 (depends on 138)

The method of claim 138, wherein the α6*nAChR inhibitor is a small molecule, an antibody, or a programmable nuclease.

### Claim 140 (depends on 138)

The method of claim 138, wherein the cancer is a colorectal cancer or a non-small cell lung cancer.

### Claim 141

A method comprising contacting a tumor comprising tumor infiltrating Tregs that express α6*nAChR with an α6*nAChR inhibitor in an amount effective to increase CD8+ T cell activation by at least 1.1 fold, relative to a control.

### Claim 142 (depends on 141)

The method of claim 141, wherein the α6*nAChR inhibitor is a small molecule, an antibody, or a programmable nuclease.

### Claim 143 (depends on 141)

The method of claim 141, wherein the cancer is a colorectal cancer or a non-small cell lung cancer.
